Abstract: The current invention concerns liver progenitor or stem cells, lysates thereof, and/or conditioned medium obtainable by culturing liver progenitor or stem cells in said medium for use in the treatment of diseases and/or conditions caused by increased vascular permeability or for use in restoring the vascular integrity of cells and tissues in a subject following inflammation and/or infection in said subject. More particularly, the present invention relates to liver progenitor or stem cells or conditioned medium obtainable by culturing liver progenitor or stem cells in said medium for therapeutic use in sepsis and sepsis-induced diseases, such as myocardial edema, acute kidney injury and lung sepsis.

Abstract: The invention relates to the use of phosphorylated Acetyl-CoA carboxylase (ACC) in platelets from a subject as a biomarker for blood coagulation, preferably blood coagulation in the subject, preferably encompassing activation of the coagulation cascade as well as platelet activation, preferably thrombin-induced platelet activation. The invention encompasses uses and methods for the diagnosis or the monitoring of blood coagulation in the subject. The invention further relates to uses and methods for screening for anti-coagulants or pro-coagulants.